Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
bexicaserin (LP352) / Longboard Pharma
NCT06660394: A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults with Dravet Syndrome (DS)	Recruiting	3	160	US	LP352, Bexicaserin, Placebo, Placebo Comparator	Longboard Pharmaceuticals	Dravet Syndrome	09/26	10/26
NCT05626634: Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	Active, not recruiting	2	50	US, RoW	LP352, bexicaserin	Longboard Pharmaceuticals	Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome	10/24	10/24
PACIFIC, NCT05364021: Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Completed	1/2	52	US, RoW	LP352, Placebo, Placebo Comparator	Longboard Pharmaceuticals	Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome	11/23	11/23
NCT06149663: Intermediate-Size Expanded Access Protocol (EAP) for LP352	Available	N/A		US	LP352	Longboard Pharmaceuticals	Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
LP143 / Longboard Pharma
No trials found
LP659 / Longboard Pharma
No trials found